位置:首页 > 产品库 > GSK2879552 dihydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
GSK2879552 dihydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
GSK2879552 dihydrochloride图片
规格:98%
分子量:437.4
包装与价格:
包装价格(元)
5mg询价
10mg询价
50mg询价
100mg询价

GSK2879552 dihydrochloride是一种可口服的,不可逆的 LSD1/ KDM1A 抑制剂,具有抗肿瘤活性。
货号:ajcx34280
CAS:1902123-72-1
分子式:C23H30Cl2N2O2
分子量:437.4
溶解度:DMSO : 50 mg/mL (114.31 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity[1][2].

GSK2879552 inhibits KDM1A histone demethylase activity, inducing differentiation of sorafenib-resistant cells and attenuates stemness properties. GSK2879552 depresses the transcription of Wnt antagonists and downregulates β-catenin signaling activity in sorafenib-resistant cells[1].

GSK2879552 (1.5 mg/kg, p.o.) treatment exhibits tumor growth inhibition in SCLC xenograft bearing mice[2].

[1]. Huang M, et al. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 2017 Apr 2;398:12-21.
[2]. Mohammad HP, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024